Explore licensed vaccines, adverse event reporting data, and history for this disease.
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Approved / Authorized Date: 2025FDA approval / licensure action (public FDA materials) |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Scientific Profile & Documentation
- Platform Architecture
- See FDA product page / label
- Lead Developer
- Novavax, Inc.
- Next Expected Milestone
- US-licensed — see product label / ACIP for use; further supplements may expand indication
- Analyst & Development Notes
- FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Protein-based COVID-19 vaccine (US pathway evolved from EUA to licensure/seasonal updates — verify current strain formulation on FDA page). May also have later supplements (strain updates, age expansions); see product page.
- Primary Source Documentation
- FDA — NUVAXOVID →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.
Milestone Overview
-
Stage VerificationApproved / Licensed confirmed as of 2026-07-10.
-
Target MilestoneUS-licensed — see product label / ACIP for use; further supplements may expand indication
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.